Haleon to Close UK Factory in Maidenhead, Resulting in Job Losses
Quote from VATcal on 01/05/2024, 19:46Consumer healthcare giant Haleon, the maker of well-known brands like Sensodyne toothpaste and Advil painkillers, has announced plans to shut its only production facility in the UK. The closure of the Maidenhead factory, located in Berkshire, will result in the loss of over 435 jobs.
Haleon, which became a separate entity after spinning off from GlaxoSmithKline (GSK) in 2022, cited a strategic review of its global manufacturing capabilities as the reason behind the closure. The company stated that the Maidenhead site is no longer considered a viable option for production.
The factory closure will be phased and is expected to be completed by the second quarter of 2026. During this period, consultations with staff will take place. Haleon has emphasised its commitment to supporting those impacted by the closure.
The decision to close the Maidenhead factory aligns with Haleon's ongoing cost-cutting efforts. The company aims to become a more streamlined organisation while maintaining a robust supply chain. Some production will be transferred to Haleon's existing facility in Slovakia.
This announcement comes amidst Haleon's broader strategy to reduce debt and streamline its portfolio. Since its spin-off from GSK, the company has shed brands like Lamisil and Chapstick to focus on core consumer healthcare products.
The closure of the Maidenhead factory is a blow to the local economy and will undoubtedly have a significant impact on the hundreds of employees who will lose their jobs. Haleon's commitment to supporting its staff during this challenging time will be closely watched.
Consumer healthcare giant Haleon, the maker of well-known brands like Sensodyne toothpaste and Advil painkillers, has announced plans to shut its only production facility in the UK. The closure of the Maidenhead factory, located in Berkshire, will result in the loss of over 435 jobs.
Haleon, which became a separate entity after spinning off from GlaxoSmithKline (GSK) in 2022, cited a strategic review of its global manufacturing capabilities as the reason behind the closure. The company stated that the Maidenhead site is no longer considered a viable option for production.
The factory closure will be phased and is expected to be completed by the second quarter of 2026. During this period, consultations with staff will take place. Haleon has emphasised its commitment to supporting those impacted by the closure.
The decision to close the Maidenhead factory aligns with Haleon's ongoing cost-cutting efforts. The company aims to become a more streamlined organisation while maintaining a robust supply chain. Some production will be transferred to Haleon's existing facility in Slovakia.
This announcement comes amidst Haleon's broader strategy to reduce debt and streamline its portfolio. Since its spin-off from GSK, the company has shed brands like Lamisil and Chapstick to focus on core consumer healthcare products.
The closure of the Maidenhead factory is a blow to the local economy and will undoubtedly have a significant impact on the hundreds of employees who will lose their jobs. Haleon's commitment to supporting its staff during this challenging time will be closely watched.
